Trident Texofab

Market Cap: Micro Cap
Industry: Garments & Apparels
ISIN: INE071Y01013
NSEID:
BSEID: 540726

INR

335.05

1.7 (0.51%)

BSENSE

Dec 05

BSE+NSE Vol: 5.1 k

{
  "main_header": {
    "sid": 1002850,
    "name": "Trident Texofab",
    "stock_name": "Trident Texofab",
    "full_name": "Trident Texofab Ltd",
    "name_url": "stocks-analysis/trident-texofab",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "335.05",
    "chg": 1.7,
    "chgp": "0.51%",
    "dir": 1,
    "prev_price": "333.35",
    "mcapval": "499.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540726,
    "symbol": "",
    "ind_name": "Garments & Apparels",
    "ind_code": 49,
    "indexname": "",
    "isin": "INE071Y01013",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "5.1 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/trident-texofab-1002850-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Trident Texofab overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-trident-texofab-overvalued-or-undervalued-3747854",
        "imagepath": "",
        "date": "2025-12-05 08:41:06",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Valuation Metrics Indicate Elevated Pricing</strong></p>\n<p>As of early December 2025, Trident Texofab’s valuation grade moved from expensive to very expensive. The company’s price-to-earnings (PE) ratio stands at an exceptionally high 171.99, signalling that investors are paying a substantial premium for each unit of earnings. This is further emphasised by a price-to-book (P/B) ratio of 8.95, which is well above typical industry averages, suggesting that the stock price is significantly higher than the company’s net asset value.</p>\n<p>Enterprise value multiples also reflect this elevated pricing. The EV to EBIT ratio is 82.13, and EV to EBITDA is 65.76, both indicating that the market values the company at many times its operating profits. The PEG ratio, which adjusts the PE ratio for earn..."
      },
      {
        "title": "Is Trident Texofab technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-trident-texofab-technically-bullish-or-bearish-3745688",
        "imagepath": "",
        "date": "2025-12-04 08:47:15",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Overview of Current Technical Position</strong></p>\n<p>As of 3 December 2025, Trident Texofab’s technical trend has shifted from bullish to mildly bullish. This subtle change indicates that while the stock retains positive momentum, the intensity of buying interest has moderated. The current market price stands at ₹336.55, slightly below the previous close of ₹343.00, and well off its 52-week high of ₹379.00, yet comfortably above the 52-week low of ₹122.90. Intraday trading on the latest session saw a high of ₹347.50 and a low of ₹336.55, reflecting some volatility but no decisive directional breakout.</p>\n<p><strong>Mixed Signals from Key Technical Indicators</strong></p>\n<p>Examining the Moving Average Convergence Divergence (MACD) reveals a divergence in timeframe perspectives. The weekl..."
      },
      {
        "title": "Trident Texofab Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/trident-texofab-technical-momentum-shifts-amid-mixed-indicator-signals-3745517",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/TridentTexofab_technicaldot_3745517.png",
        "date": "2025-12-04 08:11:53",
        "description": "Trident Texofab, a key player in the Garments & Apparels sector, has experienced notable shifts in its technical momentum, reflecting a complex interplay of market forces. Recent evaluation adjustments reveal a transition in price trends and technical indicators, signalling a nuanced outlook for investors amid fluctuating market conditions."
      },
      {
        "title": "How has been the historical performance of Trident Texofab?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-trident-texofab-3744774",
        "imagepath": "",
        "date": "2025-12-03 22:55:37",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profit Trends</strong></p>\n<p>Examining the company's net sales from March 2019 through March 2025 reveals a notable increase from ₹86.90 crores in 2019 to ₹122.06 crores in 2025. Despite some volatility, including a dip in 2021 to ₹49.93 crores, the overall trend indicates recovery and expansion. Total operating income mirrors this pattern, with no other operating income reported during this period.</p>\n<p>Operating profit before depreciation, interest, and tax (PBDIT) excluding other income showed a rise from ₹2.40 crores in 2019 to ₹5.48 crores in 2025, peaking at ₹6.31 crores in 2023. When factoring in other income, operating profit improved further, reaching ₹8.78 crores in 2025. However, interest expenses have also increased, from ₹0.86 crores in 2019 to ₹4.55 crores in 202..."
      },
      {
        "title": "Is Trident Texofab overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-trident-texofab-overvalued-or-undervalued-3713668",
        "imagepath": "",
        "date": "2025-11-19 08:10:37",
        "description": "As of 18 November 2025, the valuation grade for Trident Texofab has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently assessed as overvalued. Key ratios highlight this position, with a PE ratio of 174.34, an EV to EBITDA of 66.61, and a PEG ratio of 18.92, all suggesting that the stock is priced well above its earnings and growth potential.\n\nIn comparison to its peers, Trident Texofab's valuation appears excessive. For instance, Elitecon International has a PE ratio of 279.69, while PTC India, which is rated very attractive, has a PE of just 7.54. The stark contrast in these valuations underscores Trident Texofab's overvaluation. Additionally, while the stock has shown impressive returns over the past year, outperforming the Sensex significantly, the current valuation metrics suggest that investors may be paying too much for future grow..."
      },
      {
        "title": "Is Trident Texofab overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-trident-texofab-overvalued-or-undervalued-3709988",
        "imagepath": "",
        "date": "2025-11-18 08:26:18",
        "description": "As of 17 November 2025, the valuation grade for Trident Texofab moved from very expensive to expensive. The company is currently considered overvalued based on its high valuation ratios. The PE ratio stands at 170.80, while the EV to EBITDA ratio is 65.33, and the PEG ratio is 18.53, all significantly above typical industry benchmarks.\n\nIn comparison to its peers, Trident Texofab's valuation appears elevated; for instance, Elitecon International has a PE ratio of 294.38, indicating extreme valuation, while PTC India, which is rated very attractive, has a PE of just 7.56. Despite the company's impressive stock performance, with a year-to-date return of 100.65% compared to the Sensex's 8.72%, the current valuation metrics suggest that Trident Texofab is overvalued in the garments and apparel industry...."
      },
      {
        "title": "Why is Trident Texofab falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-trident-texofab-fallingrising-3709346",
        "imagepath": "",
        "date": "2025-11-17 23:34:27",
        "description": "As of 17-Nov, Trident Texofab Ltd's stock price is currently at Rs 337.50, reflecting an increase of Rs 9.5, or 2.9%. The stock has shown strong performance today, outperforming its sector by 2.49% and marking its fourth consecutive day of gains, with a total increase of 6.67% over this period. It opened with a significant gain of 8.08% and reached an intraday high of Rs 354.5. However, despite these positive movements, there is a notable decline in investor participation, with delivery volume dropping by 78.53% compared to the 5-day average. The stock has performed well over the long term, with a year-to-date increase of 100.65% and a remarkable 233.66% rise over the past year, although it has seen a decline of 6.69% over the past month.\n\nIn the broader market context, Trident Texofab's short-term performance has significantly outpaced the benchmark Sensex, which has only increased by 1.69% over the past w..."
      },
      {
        "title": "Trident Texofab Shows Strong Financial Performance Amid High Debt Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/trident-texofab-stock-rating-upgraded-to-hold-amid-strong-performance-3706439",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/TridentTexofab_mojoScore_3706439.png",
        "date": "2025-11-17 08:14:20",
        "description": "Trident Texofab, a microcap in the Garments & Apparels sector, has seen a recent evaluation adjustment amid strong financial performance over the past four quarters. The company has achieved significant market returns but faces challenges with a high debt-to-equity ratio and limited profitability relative to shareholders' funds."
      },
      {
        "title": "How has been the historical performance of Trident Texofab?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-trident-texofab-3705062",
        "imagepath": "",
        "date": "2025-11-15 23:11:55",
        "description": "Answer:\nThe historical performance of Trident Texofab shows a steady growth in net sales and profitability over the years, with significant fluctuations in costs and expenses.\n\nBreakdown:\nTrident Texofab's net sales have increased from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25, reflecting a strong upward trend. The total operating income has similarly risen, reaching 122.06 Cr in Mar'25 from 96.36 Cr in Mar'23. Raw material costs peaked at 23.58 Cr in Mar'23 but have since decreased to 18.68 Cr in Mar'25, while the purchase of finished goods has grown significantly from 34.09 Cr in Mar'21 to 89.02 Cr in Mar'25. Operating profit, excluding other income, was 5.48 Cr in Mar'25, down from 6.31 Cr in Mar'23, indicating some pressure on margins. Profit before tax has shown variability, with a notable increase to 2.58 Cr in Mar'25 from 1.17 Cr in Mar'24. The profit after tax also rose to 2.51 Cr in Mar'25 from 1.0..."
      }
    ],
    "total": 261,
    "sid": "1002850",
    "stock_news_url": "https://www.marketsmojo.com/news/trident-texofab-1002850"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
      "datetime": "15-Nov-2025",
      "details": "Earnings Presentation for the quarter and Half year ended September 30 2025",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "15-Nov-2025",
      "details": "Pursuant to Regulation 30 read with Schedule III Part A Para A and Regulation 47 of SEBI Listing Regulations we hereby enclose copies of newspaper advertisement published on November 15 2025 regarding extract of the Un-Audited Standalone Financial Results for the quarter and Half year ended September 30 2025",
      "source": "BSE"
    },
    {
      "caption": "Result-Financial Result For The Quarter Ended 30.09.2025",
      "datetime": "13-Nov-2025",
      "details": "The Board of Directors inter-alia has approved and taken on record Un-Audited Standalone Financial Results for the quarter and half year ended on September 30 2025 along with Limited Review Report on said results issued by the Statutory Auditor of the Company.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Trident Texofab Ltd has declared <strong>10%</strong> dividend, ex-date: 18 Jul 19",
          "dt": "2019-07-18",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Trident Texofab Ltd has announced <strong>14:10</strong> bonus issue, ex-date: 11 Aug 20",
          "dt": "2020-08-11",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Trident Texofab overvalued or undervalued?

2025-12-05 08:41:06

Valuation Metrics Indicate Elevated Pricing

As of early December 2025, Trident Texofab’s valuation grade moved from expensive to very expensive. The company’s price-to-earnings (PE) ratio stands at an exceptionally high 171.99, signalling that investors are paying a substantial premium for each unit of earnings. This is further emphasised by a price-to-book (P/B) ratio of 8.95, which is well above typical industry averages, suggesting that the stock price is significantly higher than the company’s net asset value.

Enterprise value multiples also reflect this elevated pricing. The EV to EBIT ratio is 82.13, and EV to EBITDA is 65.76, both indicating that the market values the company at many times its operating profits. The PEG ratio, which adjusts the PE ratio for earn...

Is Trident Texofab technically bullish or bearish?

2025-12-04 08:47:15

Overview of Current Technical Position

As of 3 December 2025, Trident Texofab’s technical trend has shifted from bullish to mildly bullish. This subtle change indicates that while the stock retains positive momentum, the intensity of buying interest has moderated. The current market price stands at ₹336.55, slightly below the previous close of ₹343.00, and well off its 52-week high of ₹379.00, yet comfortably above the 52-week low of ₹122.90. Intraday trading on the latest session saw a high of ₹347.50 and a low of ₹336.55, reflecting some volatility but no decisive directional breakout.

Mixed Signals from Key Technical Indicators

Examining the Moving Average Convergence Divergence (MACD) reveals a divergence in timeframe perspectives. The weekl...

Trident Texofab Technical Momentum Shifts Amid Mixed Market Signals

2025-12-04 08:11:53

Trident Texofab, a key player in the Garments & Apparels sector, has experienced notable shifts in its technical momentum, reflecting a complex interplay of market forces. Recent evaluation adjustments reveal a transition in price trends and technical indicators, signalling a nuanced outlook for investors amid fluctuating market conditions.

How has been the historical performance of Trident Texofab?

2025-12-03 22:55:37

Revenue and Profit Trends

Examining the company's net sales from March 2019 through March 2025 reveals a notable increase from ₹86.90 crores in 2019 to ₹122.06 crores in 2025. Despite some volatility, including a dip in 2021 to ₹49.93 crores, the overall trend indicates recovery and expansion. Total operating income mirrors this pattern, with no other operating income reported during this period.

Operating profit before depreciation, interest, and tax (PBDIT) excluding other income showed a rise from ₹2.40 crores in 2019 to ₹5.48 crores in 2025, peaking at ₹6.31 crores in 2023. When factoring in other income, operating profit improved further, reaching ₹8.78 crores in 2025. However, interest expenses have also increased, from ₹0.86 crores in 2019 to ₹4.55 crores in 202...

Is Trident Texofab overvalued or undervalued?

2025-11-19 08:10:37

As of 18 November 2025, the valuation grade for Trident Texofab has moved from expensive to very expensive, indicating a significant shift in its market perception. The company is currently assessed as overvalued. Key ratios highlight this position, with a PE ratio of 174.34, an EV to EBITDA of 66.61, and a PEG ratio of 18.92, all suggesting that the stock is priced well above its earnings and growth potential. In comparison to its peers, Trident Texofab's valuation appears excessive. For instance, Elitecon International has a PE ratio of 279.69, while PTC India, which is rated very attractive, has a PE of just 7.54. The stark contrast in these valuations underscores Trident Texofab's overvaluation. Additionally, while the stock has shown impressive returns over the past year, outperforming the Sensex significantly, the current valuation metrics suggest that investors may be paying too much for future grow...

Is Trident Texofab overvalued or undervalued?

2025-11-18 08:26:18

As of 17 November 2025, the valuation grade for Trident Texofab moved from very expensive to expensive. The company is currently considered overvalued based on its high valuation ratios. The PE ratio stands at 170.80, while the EV to EBITDA ratio is 65.33, and the PEG ratio is 18.53, all significantly above typical industry benchmarks. In comparison to its peers, Trident Texofab's valuation appears elevated; for instance, Elitecon International has a PE ratio of 294.38, indicating extreme valuation, while PTC India, which is rated very attractive, has a PE of just 7.56. Despite the company's impressive stock performance, with a year-to-date return of 100.65% compared to the Sensex's 8.72%, the current valuation metrics suggest that Trident Texofab is overvalued in the garments and apparel industry....

Why is Trident Texofab falling/rising?

2025-11-17 23:34:27

As of 17-Nov, Trident Texofab Ltd's stock price is currently at Rs 337.50, reflecting an increase of Rs 9.5, or 2.9%. The stock has shown strong performance today, outperforming its sector by 2.49% and marking its fourth consecutive day of gains, with a total increase of 6.67% over this period. It opened with a significant gain of 8.08% and reached an intraday high of Rs 354.5. However, despite these positive movements, there is a notable decline in investor participation, with delivery volume dropping by 78.53% compared to the 5-day average. The stock has performed well over the long term, with a year-to-date increase of 100.65% and a remarkable 233.66% rise over the past year, although it has seen a decline of 6.69% over the past month. In the broader market context, Trident Texofab's short-term performance has significantly outpaced the benchmark Sensex, which has only increased by 1.69% over the past w...

Trident Texofab Shows Strong Financial Performance Amid High Debt Concerns

2025-11-17 08:14:20

Trident Texofab, a microcap in the Garments & Apparels sector, has seen a recent evaluation adjustment amid strong financial performance over the past four quarters. The company has achieved significant market returns but faces challenges with a high debt-to-equity ratio and limited profitability relative to shareholders' funds.

How has been the historical performance of Trident Texofab?

2025-11-15 23:11:55

Answer: The historical performance of Trident Texofab shows a steady growth in net sales and profitability over the years, with significant fluctuations in costs and expenses. Breakdown: Trident Texofab's net sales have increased from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25, reflecting a strong upward trend. The total operating income has similarly risen, reaching 122.06 Cr in Mar'25 from 96.36 Cr in Mar'23. Raw material costs peaked at 23.58 Cr in Mar'23 but have since decreased to 18.68 Cr in Mar'25, while the purchase of finished goods has grown significantly from 34.09 Cr in Mar'21 to 89.02 Cr in Mar'25. Operating profit, excluding other income, was 5.48 Cr in Mar'25, down from 6.31 Cr in Mar'23, indicating some pressure on margins. Profit before tax has shown variability, with a notable increase to 2.58 Cr in Mar'25 from 1.17 Cr in Mar'24. The profit after tax also rose to 2.51 Cr in Mar'25 from 1.0...

View All News

Announcement

Announcement under Regulation 30 (LODR)-Investor Presentation

15-Nov-2025 | Source : BSE

Earnings Presentation for the quarter and Half year ended September 30 2025

Announcement under Regulation 30 (LODR)-Newspaper Publication

15-Nov-2025 | Source : BSE

Pursuant to Regulation 30 read with Schedule III Part A Para A and Regulation 47 of SEBI Listing Regulations we hereby enclose copies of newspaper advertisement published on November 15 2025 regarding extract of the Un-Audited Standalone Financial Results for the quarter and Half year ended September 30 2025

Result-Financial Result For The Quarter Ended 30.09.2025

13-Nov-2025 | Source : BSE

The Board of Directors inter-alia has approved and taken on record Un-Audited Standalone Financial Results for the quarter and half year ended on September 30 2025 along with Limited Review Report on said results issued by the Statutory Auditor of the Company.